Brokerages Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $26.50

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been assigned an average rating of “Reduce” from the nine analysts that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $26.50.

Several research analysts have recently weighed in on IART shares. Morgan Stanley upped their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Citigroup decreased their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a report on Tuesday, October 1st. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Finally, Bank of America cut their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th.

Integra LifeSciences Trading Down 1.2 %

Shares of IART stock opened at $18.88 on Friday. The company’s fifty day simple moving average is $18.84 and its two-hundred day simple moving average is $25.16. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $45.42. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of 37.76, a PEG ratio of 0.62 and a beta of 1.09.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. The business had revenue of $418.20 million for the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.71 EPS. As a group, analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the business. Capital Research Global Investors boosted its position in Integra LifeSciences by 37.7% during the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after buying an additional 1,621,655 shares during the period. Jane Street Group LLC boosted its holdings in shares of Integra LifeSciences by 181.1% during the first quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company’s stock worth $4,427,000 after purchasing an additional 80,463 shares during the period. Leeward Investments LLC MA boosted its holdings in shares of Integra LifeSciences by 17.8% during the first quarter. Leeward Investments LLC MA now owns 452,438 shares of the life sciences company’s stock worth $16,039,000 after purchasing an additional 68,247 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Integra LifeSciences by 606.9% during the second quarter. SG Americas Securities LLC now owns 67,471 shares of the life sciences company’s stock worth $1,966,000 after purchasing an additional 57,927 shares during the period. Finally, Boston Partners purchased a new stake in shares of Integra LifeSciences during the first quarter worth about $19,383,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.